8-K: IN8bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

IN8bio announced its first quarter 2024 financial results, highlighting progress in its gamma-delta T cell therapy programs and the advancement of its clinical trials.

Summary

• IN8bio reported its financial results for the first quarter of 2024, ending March 31, 2024.
• The company's research and development expenses increased to $4.9 million, up from $4.4 million in the same period last year, due to increased personnel costs and clinical trial expenses.
• General and administrative expenses also rose to $3.7 million, compared to $3.5 million in the prior year, primarily due to increased personnel costs.
• The net loss for the quarter was $8.6 million, or $0.20 per share, compared to a net loss of $7.5 million, or $0.30 per share, in the first quarter of 2023.
• As of March 31, 2024, IN8bio had $13.0 million in cash, down from $21.3 million at the end of 2023.
• The company presented new preclinical data on its non-signaling Chimeric Antigen Receptor (nsCAR) platform at the AACR 2024 Annual Meeting.
• IN8bio also announced the first patient dosed in the Phase 2 autologous arm of the INB-400 clinical trial for newly diagnosed glioblastoma multiforme (GBM).

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in the clinical programs and technology, the increasing net loss and decreasing cash position are concerning. The sentiment is neutral to slightly negative due to the financial results.

Positives

• The nsCAR platform shows promise in targeting cancer cells while preserving healthy tissue, potentially reducing off-target toxicity.
• The DeltEx DRI approach for GBM has been published in a peer-reviewed journal, validating its scientific basis.
• The initiation of patient dosing in the Phase 2 autologous arm of INB-400 is a significant milestone.
• The company has multiple upcoming presentations at major medical conferences, which will provide further data on their clinical programs.
• IN8bio has robust capabilities in complex cell therapy process development and manufacturing.

Negatives

• The company's net loss increased to $8.6 million in the first quarter of 2024, compared to $7.5 million in the same period last year.
• IN8bio's cash position decreased from $21.3 million at the end of 2023 to $13.0 million as of March 31, 2024.
• Research and development expenses and general and administrative expenses have increased year-over-year.

Risks

• The company faces risks related to site initiation, clinical trial commencement, patient enrollment, and follow-up.
• Public health crises, rising inflation, and regulatory developments could impact the company's ability to meet anticipated deadlines and milestones.
• There are uncertainties inherent in the initiation and completion of preclinical studies and clinical trials.
• The company relies on third parties, including licensors and clinical research organizations, which could pose risks.
• There is a risk that the outcomes of preclinical studies may not be predictive of clinical trial results.

Future Outlook

IN8bio anticipates several upcoming milestones, including presentations at medical conferences, enrollment of additional patients in clinical trials, and potential submission of an IND application for a Phase 2 trial for INB-100. The company expects to treat up to 40 patients in the Phase 2 autologous arm of INB-400.

Management Comments

• William Ho, CEO and co-founder of IN8bio, stated that the company continued to make significant progress advancing its gamma-delta T cell programs in the first quarter of 2024.
• William Ho highlighted the potential of the nsCAR platform to target and kill various acute myeloid leukemia (AML) cells while preserving healthy bone marrow cells.

Industry Context

The announcement aligns with the broader industry trend of developing innovative cell-based immunotherapies for cancer treatment. The focus on gamma-delta T cells and novel approaches like nsCAR reflects the industry's pursuit of more effective and less toxic therapies. The company is competing with other companies in the cell therapy space, particularly those focused on CAR T-cell therapies and other forms of immunotherapy.

Comparison to Industry Standards

• IN8bio's focus on gamma-delta T cells is a differentiating factor compared to the more common alpha-beta CAR T-cell therapies, such as those developed by companies like Novartis (Kymriah) and Gilead (Yescarta).
• The development of the nsCAR platform is an attempt to address the toxicity issues associated with traditional CAR T-cell therapies, which is a common challenge in the industry.
• The company's clinical trial progress in GBM and hematologic malignancies is comparable to other biotech companies in the early to mid-stage clinical development phase.
• The cash burn rate and net loss are typical for a clinical-stage biotech company, but the decrease in cash position is a concern that will need to be addressed.
• The publication of the DeltEx DRI approach in a peer-reviewed journal is a positive sign of scientific validation, which is important for attracting investors and partners.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash position.
• Employees may be impacted by the company's financial performance and future plans.
• Patients may benefit from the advancement of IN8bio's clinical programs.
• Suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• IN8bio will present updated interim results from the ongoing Phase 1 investigator-sponsored trial of INB-100 at the 2024 EHA Annual Meeting in June.
• The company will potentially submit an IND application for a Phase 2 registrational trial in 2024 for INB-100.
• IN8bio will report interim Phase 1 long-term follow up results in GBM at multiple medical meetings in 2024, including at the 2024 ASCO Annual Meeting.
• The company expects to treat up to a total of 40 patients in arm A of the INB-400 trial.

Key Dates

Keywords

IN8bio, gamma-delta T cell therapy, nsCAR, DeltEx DRI, glioblastoma multiforme, AML, clinical trials, immunotherapy, cancer, biopharmaceutical